Fig. 6

Therapeutic efficacy of CUDC-907 and olaparib as single-agents or in combination in vivo. a, b) Tumor volume curves (a) and tumor weights (b) of SCLC PDX tumors treated with CUDC-907, olaparib, or a combination of CUDC-907 and olaparib. c Representative immunohistochemistry images of Ki67, cleaved-caspase3 (CC3), c-MYC, Rad51, and Ku80 on PDX tumors treated with CUDC-907 and olaparib alone or in combination. Scale bar, 100 μm